Mel Krajden

23.4k total citations · 1 hit paper
367 papers, 11.8k citations indexed

About

Mel Krajden is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Mel Krajden has authored 367 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 276 papers in Epidemiology, 153 papers in Hepatology and 102 papers in Infectious Diseases. Recurrent topics in Mel Krajden's work include Hepatitis C virus research (145 papers), Hepatitis B Virus Studies (126 papers) and Liver Disease Diagnosis and Treatment (90 papers). Mel Krajden is often cited by papers focused on Hepatitis C virus research (145 papers), Hepatitis B Virus Studies (126 papers) and Liver Disease Diagnosis and Treatment (90 papers). Mel Krajden collaborates with scholars based in Canada, United States and Australia. Mel Krajden's co-authors include Danuta M. Skowronski, Martin Petric, Gina Ogilvie, Naveed Z. Janjua, Darrel Cook, Mark Tyndall, Jason Grebely, Mark Gilbert, Gaston De Serres and Nathalie Bastien and has published in prestigious journals such as New England Journal of Medicine, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Mel Krajden

356 papers receiving 11.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of Severe Acute Respiratory Syndrome in Canada

2003 867 citations Bonnie Henry, Danuta M. Skowronski et al. profile →

Peers

Countries citing papers authored by Mel Krajden

Since Specialization

Citations

This map shows the geographic impact of Mel Krajden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mel Krajden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mel Krajden more than expected).

Fields of papers citing papers by Mel Krajden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mel Krajden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mel Krajden. The network helps show where Mel Krajden may publish in the future.

Co-authorship network of co-authors of Mel Krajden

This figure shows the co-authorship network connecting the top 25 collaborators of Mel Krajden. A scholar is included among the top collaborators of Mel Krajden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mel Krajden. Mel Krajden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Expanding access to healthcare for people who use drugs and sex workers: hepatitis C elimination implications from a qualitative study of healthcare experiences in British Columbia, Canada 2024 ·Harm Reduction Journal ·(unknown), (unknown), (unknown), Mel Krajden, Robert S. Hogg, Angela Towle, Viviane D. Lima, Kate Salters	2
2	Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study 2024 ·Cancer Epidemiology Biomarkers & Prevention ·Anna Gottschlich, Quan Hong, Lovedeep Gondara, (unknown), Darrel Cook, Ruth Elwood Martin, Marette Lee, Joy Melnikow, Stuart Peacock, Lily Proctor, Gavin Stuart, Eduardo L. Franco, Mel Krajden, Laurie Smith, Gina Ogilvie	1
3	Impact of COVID‐19 pandemic on hepatocellular carcinoma surveillance in British Columbia, Canada: An interrupted time series study 2024 ·Journal of Viral Hepatitis ·Jean Damascène Makuza, Stanley Wong, Richard L. Morrow, Mawuena Binka, Maryam Darvishian, Dahn Jeong, Prince Adu, (unknown), Amanda Yu, Héctor Alexander Velásquez García, Sofia Bartlett, Eric M. Yoshida, Alnoor Ramji, Mel Krajden, Naveed Z. Janjua	2
4	Clinical utility and interpretive guidance for SARS-CoV-2 serological testing 2023 ·Clinical Microbiology Newsletter ·Muhammad Morshed, Agatha N. Jassem, (unknown), (unknown), Mel Krajden, Inna Sekirov	0
5	Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID‐19 serological assays as a proof of concept 2023 ·Vox Sanguinis ·(unknown), (unknown), Chelsea Caya, Matthew P. Cheng, Karen Colwill, Rachel Corsini, Anne‐Claude Gingras, Agatha N. Jassem, Mel Krajden, Ana Márquez, Bruce Mazer, (unknown), Christian Renaud, Cédric P. Yansouni, Jesse Papenburg, Antoine Lewin	2
6	Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study 2023 ·The Lancet Regional Health - Americas ·Anna Gottschlich, Lovedeep Gondara, Laurie Smith, (unknown), Darrel Cook, Mel Krajden, Marette Lee, Ruth Elwood Martin, Joy Melnikow, Stuart Peacock, Lily Proctor, Gavin Stuart, Eduardo L. Franco, Dirk van Niekerk, Gina Ogilvie	3
7	Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada 2022 ·The Journal of Infectious Diseases ·Danuta M. Skowronski, Solmaz Setayeshgar, Macy Zou, Natalie Prystajecky, John R. Tyson, Hind Sbihi, Christopher D. Fjell, Eleni Galanis, Monika Naus, David M. Patrick, (unknown), (unknown), Shinhye Kim, Bonnie Henry, Linda Hoang, Manish Sadarangani, Agatha N. Jassem, Mel Krajden	7
8	Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study 2022 ·Clinical Infectious Diseases ·Sharifa Nasreen, (unknown), Héctor Alexander Velásquez García, Geng Zhang, Mina Tadrous, Sarah A. Buchan, Christiaan H. Righolt, Salaheddin M. Mahmud, Naveed Z. Janjua, Mel Krajden, Gaston De Serres, Jeffrey C. Kwong	8
9	British Columbia’s Experience after Implementation of the Treponema pallidum Reverse Algorithm and PCR Detection, 2015 to 2020 2022 ·Microbiology Spectrum ·Muhammad Morshed, Min-Kuang Lee, (unknown), Darrel Cook, Annie Mak, (unknown), (unknown), Carolyn A. Montgomery, (unknown), (unknown), (unknown), Troy Grennan, Jason Wong, Mel Krajden	5
10	Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada 2021 ·Clinical Infectious Diseases ·Danuta M. Skowronski, Solmaz Setayeshgar, Macy Zou, Natalie Prystajecky, John R. Tyson, Eleni Galanis, Monika Naus, David M. Patrick, Hind Sbihi, (unknown), Bonnie Henry, Linda Hoang, Manish Sadarangani, Agatha N. Jassem, Mel Krajden	35
11	Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result 2021 ·American Journal of Obstetrics and Gynecology ·(unknown), Anna Gottschlich, Darrel Cook, Laurie Smith, Lovedeep Gondara, Eduardo L. Franco, Dirk J. van Niekerk, Gina Ogilvie, Mel Krajden	10
12	SARS-CoV-2 serology: Validation of high-throughput chemiluminescent immunoassay (CLIA) platforms and a field study in British Columbia 2021 ·Journal of Clinical Virology ·Inna Sekirov, Vilte Barakauskas, Janet Simons, Darrel Cook, (unknown), Laura Burns, (unknown), Marthe Charles, (unknown), Annie Mak, (unknown), Rohit Vijh, (unknown), David A. Goldfarb, Paul N. Levett, Mel Krajden, Muhammad Morshed	12
13	Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study 2021 ·Journal of Hepatology ·Naveed Z. Janjua, Stanley Wong, (unknown), Dahn Jeong, (unknown), Prince Adu, Hasina Samji, James Wilton, Margo Pearce, Zahid A Butt, Amanda Yu, Mawuena Binka, Sofia Bartlett, Maria Alvarez, Mel Krajden	38
14	Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study 2020 ·Open Forum Infectious Diseases ·James Wilton, Stanley Wong, Amanda Yu, Alnoor Ramji, Darrel Cook, Zahid A Butt, Maria Alvarez, Mawuena Binka, Maryam Darvishian, Dahn Jeong, Sofia Bartlett, Margo Pearce, Prince Adu, Eric M. Yoshida, Mel Krajden, Naveed Z. Janjua	26
15	The impact of SVR from direct‐acting antiviral‐ and interferon‐based treatments for HCV on hepatocellular carcinoma risk 2020 ·Journal of Viral Hepatitis ·Naveed Z. Janjua, Stanley Wong, Maryam Darvishian, Zahid A Butt, Amanda Yu, Mawuena Binka, Maria Alvarez, Ryan Woods, Eric M. Yoshida, Alnoor Ramji, Jordan J. Feld, Mel Krajden	37
16	Disease detection at the 48‐month exit round of the HPV FOCAL cervical cancer screening trial in women per‐protocol eligible for routine screening 2019 ·International Journal of Cancer ·Andrew J. Coldman, Dirk van Niekerk, Mel Krajden, Laurie Smith, Darrel Cook, Lovedeep Gondara, Kathy Ceballos, (unknown), Marette Lee, (unknown), Laura Gentile, Stuart Peacock, Gavin Stuart, Eduardo L. Franco, Gina Ogilvie	2
17	Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial 2018 ·Journal of Clinical Virology ·Darrel Cook, Laurie Smith, Jennifer Law, (unknown), Lovedeep Gondara, Dirk J. van Niekerk, Kathy Ceballos, Dan Jang, Max Chernesky, Eduardo L. Franco, Gina Ogilvie, Andrew J. Coldman, Mel Krajden	15
18	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial 2018 ·Obstetrical & Gynecological Survey ·Gina Ogilvie, Dirk van Niekerk, Mel Krajden, Laurie Smith, Darrel Cook, Lovedeep Gondara, Kathy Ceballos, David Quinlan, Marette Lee, Ruth Elwood Martin, Laura Gentile, Stuart Peacock, Gavin Stuart, Eduardo L. Franco, Andrew J. Coldman	32
19	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study 2017 ·Journal of Viral Hepatitis ·Maryam Alavi, Naveed Z. Janjua, Mei Chong, Jason Grebely, Esther Aspinall, Hamish Innes, Heather Valerio, Behzad Hajarizadeh, P C Hayes, Mel Krajden, Janaki Amin, Matthew Law, Jacob George, David Goldberg, Sharon Hutchinson, Gregory J. Dore	15
20	Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing 2016 ·Infection Genetics and Evolution ·Vincent Montoya, Andrea D. Olmstead, Patrick Tang, Darrel Cook, Naveed Z. Janjua, Jason Grebely, Brendan Jacka, Art F. Y. Poon, Mel Krajden	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact